MAP2K7 and melanoma: Reasons for excluding patients from the analyses were premature discontinuation of the breathing test due to shortness of breath (n=5), non-melanoma related death before response evaluation (n=2), temporarily device defect (n=2), withdrawal of informed consent (n=1), and concurrent treatment with BRAF/MEK inhibitors before the first response evaluation (n=1).